Patient-Reported Outcomes
Our studies assess the value of pharmaceutical products and devices from the patient’s perspective. We evaluate patient-reported outcomes using a variety of data sources, including patient survey data, focus group data, interviews, and clinical trials. Our experience includes:
- Developing and validating patient-reported outcomes (PRO) instruments
- Analyzing clinical trial data to demonstrate treatment efficacy using PRO instruments
- Developing PRO evidence for dossiers in connection with label consideration
- Establishing the minimal clinically important difference (MCID) for PRO instruments
- Developing interactive tools to communicate the health-related quality of life (HRQL) burden of a disease
- Designing patient surveys and conducting primary data collection to assess the HRQL of a disease
- Designing and carrying out discrete choice experiment (DCE) studies to investigate patients’ preferences and willingness to pay for medical products
Selected Recent Examples of Our Work
- Stein EM, Yang M, Guerin A, Gao W, Galebach P, Xiang CQ, Bhattacharyya S, Bonifacio G, Joseph GJ. Assessing Utility Values for Treatment-Related Health States of Acute Myeloid Leukemia in the United States. Health and Quality of Life Outcomes2018;16:193
- Papp KA, Yang M, Sundaram M, Jarvis J, Betts K, Bao Y, Signorovitch JE. Comparison of Adalimumab and Etanercept for the Treatment of Moderate-to-Severe Psoriasis: an Indirect Comparison using Individual Patient Data from Randomized Trials. Value in Health 2018; 21:1-8
- Crowley J, Skup M, Huang X, Yang M, Wu EQ, Thompson E, Zema C, Reich K. "Patient-Reported Outcomes from the IMMVent Trial: Comparison of Risankizumab with Adalimumab in Moderate to Severe Psoriasis Patients" at the European Academy of Dermatology and Venereology (EADV) 27th Congress, September 12 - 16, 2018, Paris, France
- Augustin M, Lambert J, Zema C, Thompson E, Yang M, Wu EQ, Geng Z, Valdes J, Skup M, Gordon M. "Risankizumab Significantly Improves Patient-Reported Outcomes in Moderate to Severe Psoriasis in Two Phase III UltIMMa Trials" at the European Academy of Dermatology and Venereology (EADV) 27th Congress, September 12 - 16, 2018, Paris, France
- Ryan C, Puig L, Zema C, Thompson E, Yang M, Wu EQ, Huang X, Skup M, Elewski B. "Incremental benefits on patient-reported outcomes for achieving PASI90 or PASI100 over PASI75 in patients with moderate to severe psoriasis" at the European Academy of Dermatology and Venereology (EADV) 27th Congress, September 12 - 16, 2018, Paris, France
- Tundia N, Zhou J, Yang M, Macaulay D, Curtis JR. "Burden of Work Instability in Patients with Rheumatoid Arthritis in US and Its Association with Work Productivity and Transitions" at the Academy of Managed Care & Specialty Pharmacy (AMCP) Annual Meeting 2018, April 23-26, 2018, Boston, Massachusetts
- Husni ME, Betts KA, Griffith J, et al. Benefit‑risk trade‑offs for treatment decisions in moderate‑to‑severe rheumatoid arthritis: focus on the patient perspective. Rheumatology International 2017; 37:1423-1434
- Li J, Houleb CR, Spaldingb JR, Yang H,et al. Attributes of nuclear imaging centers impacting physician referrals for single-photon emission computed tomography myocardial perfusion imaging tests. Journal of Medical Economics 2017; 20:777-785
- Welzel TM, Yang M, Sajeev G, Pinsky B, Mehta D, Bao Y, Wu E, Chen YJ. "Assessing Patient Preferences for and Relative Importance of Features of New Direct Acting Antiviral (DAA) Treatments for Chronic Hepatitis C Virus (HCV) Infections" at the American Association for the Study of Liver Disease 68th Annual Meeting, October 20-24, 2017, Washington, DC
- Kimball A, Yang M, Song Y, Valdecantos W, Ganguli. “Health-related quality of life and work productivity associated with HiSCR and NRS30 response among patients with moderate to severe” at the American Academy of Dermatology 75th Annual Meeting, March 3-7, 2017, Orlando, FL
